Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Liver Cancer
Interventions
DRUG

Oxaliplatin

Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.

DRUG

Irofulven

Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.

Trial Locations (7)

Unknown

Bordeaux

Clichy

Lyon

Nice

Paris

Poitiers

Saint-Cloud

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00374660 - Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter